AAM
BBIO icon

Advisors Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Advisors Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$814K Sell
10,965
-1,557
-12% -$113K 0.01% 849
2025
Q4 		$958K Sell
12,522
-134
-1% -$8.8K 0.02% 799
2025
Q3 		$657K Sell
12,656
-47
-0.4% -$2.29K 0.01% 912
2025
Q2 		$549K Buy
12,703
+3
+0% +$109 0.01% 926
2025
Q1 		$439K Buy
12,700
+3,687
+41% +$124K 0.01% 966
2024
Q4 		$247K Buy
9,013
+4,437
+97% +$115K ﹤0.01% 1085
2024
Q3 		$117K Buy
4,576
+1,645
+56% +$43.2K ﹤0.01% 1198
2024
Q2 		$74.2K Buy
+2,931
New +$80.1K ﹤0.01% 1238

Other funds holding BBIO

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return